Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Hepatitis: early-phase trial registry

1 of 6 indexed Hepatitis trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · 1 currently recruiting · #2,866 of 28,707 conditions by registered trial count

Hepatitis: 6 US clinical trials tracked, 1 recruiting.

Hepatitis is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), running 2 of these trials.

Enrollment posture brief

Registry condition hepatitis

OPEN 1 | RECR 17% | LATE 1 | EARLY 2 | RANK #2866 | SPON 2

Nearest open-share peer: Acute Renal Failure (17% recruiting · 6 trials)

Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%Hepatitis (this)17%
Open-enrollment share among volume-matched conditions near Hepatitis

Hepatitis lists 1 open slots (17% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Hepatitis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Hepatitis is recruiting below its size-band peers.

    1 of 6 indexed trials (16.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Hepatitis research.

    National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) accounts for 2 of 6 trials (33.3%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Typical Hepatitis enrolment sits around 315 participants.

    Median target enrolment is 315 among the 6 trials that report a genuine target (sentinel values excluded). 2 of those (33.3%) plan for fewer than 100 participants.

  4. Hepatitis splits between interventional and observational designs.

    4 interventional and 2 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 22Phase 31

Phase Distribution

PhaseTrial count
Phase 2 2
Phase 3 1

Named interventions

Most-linked intervention names on Hepatitis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

HARP Intervention Behavioral
1 trials
Ribavirin (Copegus®) Drug
1 trials
PEG-Interferon-alpha 2a (Pegasys®) Drug
1 trials
Merimepodib Drug
1 trials
Actos (Pioglitazone) Drug
1 trials
Larsucosterol Drug
1 trials
Placebo Drug
1 trials

US sites by state

Facility locations filed on Hepatitis trials. A trial with sites in several states counts in each.

Georgia 2 trials
Texas 1 trials
Pennsylvania 1 trials
New York 1 trials
Maryland 1 trials
Illinois 1 trials
Idaho 1 trials
Florida 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Hepatitis page

6 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hepatitis condition card totals 6 registered trials; most-linked intervention HARP Intervention; top US site state Georgia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.